Mode
Text Size
Log in / Sign up

Oncology

1582 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Combined SHOX2 and RASSF1A methylation provides superior diagnostic performance for lung cancer detection
Oncology Meta-analysis
Combined SHOX2 and RASSF1A methylation provides superior diagnostic performance for lung cancer detection Combined Biomarkers Show Better Accuracy for Lung Cancer Diagnosis
This meta-analysis of 49 studies evaluates the diagnostic performance of SHOX2 and RASSF1A methylation in lung cancer. The combined methylat…
Combining two specific genetic markers, SHOX2 and RASSF1A, may provide a more accurate way to detect lung cancer than using either one alone…
ctDNA-guided adjuvant immunotherapy improves survival outcomes in patients with muscle-invasive urothelial carcinoma
Oncology Meta-analysis
ctDNA-guided adjuvant immunotherapy improves survival outcomes in patients with muscle-invasive urothelial carcinoma ctDNA Testing May Help Guide Immunotherapy for Bladder Cancer
Researchers evaluated the impact of ctDNA-guided or ctDNA-stratified adjuvant immunotherapy on patients with muscle-invasive urothelial carc…
New analysis suggests using ctDNA tests to guide immunotherapy for patients with muscle-invasive urothelial carcinoma after surgery.
Tele-robot-assisted prostatectomy achieves 100% technical success in small case series
Oncology Meta-analysis
Tele-robot-assisted prostatectomy achieves 100% technical success in small case series Remote Robot Prostate Surgery Shows Promise in Early Data
This meta-analysis of small case series found that tele-robot-assisted prostatectomy achieved a 100% technical success rate (80/80) with no …
Remote-controlled robot prostate surgery succeeded in all 80 patients, with no severe complications, but the evidence is early.
DLL3-directed therapy shows early activity in biomarker-selected neuroendocrine prostate cancer cases
Oncology Sys. Review
DLL3-directed therapy shows early activity in biomarker-selected neuroendocrine prostate cancer cases New research explores ways to treat neuroendocrine prostate cancer
This narrative review explores the tumor microenvironment (TME) and DLL3-directed therapy in neuroendocrine prostate cancer (NEPC). The revi…
New research looks at how the environment around tumors might help target and treat a specific, aggressive form of prostate cancer.
FDA Approves Tevimbra (tislelizumab-jsgr) for Esophageal and Gastric Cancers
Oncology FDA Approval
FDA Approves Tevimbra (tislelizumab-jsgr) for Esophageal and Gastric Cancers FDA approves new drug Tevimbra for two types of stomach and esophagus cancer.
The FDA approved Tevimbra (tislelizumab-jsgr) for first-line treatment of PD-L1-positive unresectable or metastatic esophageal squamous cell…
The FDA approved Tevimbra (tislelizumab-jsgr) for certain esophageal and stomach cancers. It is used alone or with chemotherapy for patients…
FDA Approves Ziihera (zanidatamab-hrii) for HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancer
Oncology FDA Approval
FDA Approves Ziihera (zanidatamab-hrii) for HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancer FDA approves new drug Ziihera for two types of cancer
The FDA approved Ziihera (zanidatamab-hrii) for first-line treatment of HER2-positive gastroesophageal adenocarcinoma in combination with ch…
The FDA has approved Ziihera for two HER2-positive cancers: stomach and bile duct. It offers a new targeted treatment option. This approval …
Systemic therapies may complicate radiation-induced lung injury by sustaining inflammation or delaying repair
Oncology Sys. Review
Systemic therapies may complicate radiation-induced lung injury by sustaining inflammation or delaying repair Systemic Treatments May Affect Radiation Lung Injury Recovery
This narrative review examines the management of pulmonary events in patients receiving thoracic radiotherapy and combination anticancer the…
New clinical perspectives help doctors distinguish between radiation damage and complications caused by systemic cancer treatments in lung p…
Bioactive compounds from aromatic plants show potent cytotoxic activities in various preclinical cancer models
Oncology Meta-analysis
Bioactive compounds from aromatic plants show potent cytotoxic activities in various preclinical cancer models Aromatic plants may contain compounds that fight cancer cells
This systematic review examines the anticancer potential of bioactive compounds from underexplored aromatic plants, including monoterpenes a…
Certain compounds found in aromatic plants show promise in lab tests against cancer, but more human trials are needed to confirm their safet…
Splicing-derived neoantigens provide diverse target classes for T-cell and antibody-based cancer immunotherapies
Oncology Sys. Review
Splicing-derived neoantigens provide diverse target classes for T-cell and antibody-based cancer immunotherapies Splicing-Derived Neoantigens Offer New Targets for Cancer Immunotherapy
This systematic review explores splicing-derived neoantigens as potential targets for cancer immunotherapy. The review identifies two major …
New research identifies splicing-derived neoantigens as a promising source of specific targets for T-cell and antibody-based cancer treatmen…
D-VCd improves hematologic CR rate to 59.5% compared to 19.2% in AL amyloidosis
Oncology RCT
D-VCd improves hematologic CR rate to 59.5% compared to 19.2% in AL amyloidosis Trial shows adding daratumumab improves outcomes for AL amyloidosis
This Phase 3 randomized controlled trial of 388 patients with newly diagnosed AL amyloidosis found that adding subcutaneous daratumumab to V…
Adding daratumumab to a standard drug combination helps patients with AL amyloidosis achieve faster and deeper responses in blood and organ …
HER2, PD-L1, MSI/MMR, and CLDN18.2 biomarkers may guide treatment selection in gastric cancer conversion therapy
Oncology Sys. Review
HER2, PD-L1, MSI/MMR, and CLDN18.2 biomarkers may guide treatment selection in gastric cancer conversion therapy Biomarkers help doctors choose better treatments for gastric cancer
This narrative review explores the clinical utility of HER2, PD-L1, MSI/MMR, and CLDN18.2 biomarkers in patients with gastric cancer undergo…
New markers like HER2 and CLDN18.2 help doctors identify which gastric cancer patients might respond best to specific therapies before surge…
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.